Business Context and Reporting Period
This Form 8-K is filed by AmerisourceBergen Corporation (now Cencora, Inc.) for the reporting period of October 3, 2005. The filing details the entry into a material definitive credit agreement and the completion of a significant asset acquisition in Canada.
Key Financial Metrics and Transactions
- Credit Facility: Entered into a CAN$135 million senior unsecured credit facility (Canadian Credit Agreement) with a maturity date of December 2009.
- Acquisition Cost: Acquired Trent Drugs (Wholesale) Ltd. for a total purchase price of approximately US$83 million.
- Debt Assumption: The acquisition included the assumption of approximately US$43 million in debt.
- Financing: The acquisition was financed through borrowings under the new Canadian Credit Agreement.
- Interest Rates: Borrowing rates range from 0.32% to 1.20% over LIBOR and 0% to 0.20% over ABR or CPR, depending on debt ratings.
- Facility Fees: Quarterly fees range from 0.08% to 0.30% of the total commitment.
Material Changes
The primary material change is the expansion of the company's operations into the Canadian pharmaceutical distribution market through the acquisition of Trent Drugs (Wholesale) Ltd., described as one of the largest national distributors in Canada. This transaction was executed via a wholly-owned Canadian subsidiary, which was subsequently amalgamated with the acquired entity.
Outlook, Risks, and Covenants
- Use of Funds: Proceeds are designated for general corporate purposes, investments, and acquisitions, specifically funding the Trent Drugs acquisition and ongoing Canadian operations.
- Covenants: The credit agreement imposes restrictions on additional indebtedness, distributions, dividends, investments, and loans. It also mandates compliance with leverage and fixed charge coverage ratios.
- Guarantees: AmerisourceBergen Corporation acts as the guarantor for the subsidiary's obligations under the credit agreement.
- Flexibility: The borrower may repay obligations or reduce commitments at any time.
Investor Verification Checklist
- Verify the exact exchange rate used to convert the CAN$135 million facility and US$83 million purchase price for accurate financial modeling.
- Confirm the specific debt rating of the Borrower to determine the applicable interest rate spread and facility fees.
- Review the consolidated balance sheet to assess the impact of the US$43 million debt assumption on the company's overall leverage ratios.
- Examine the news release filed as Exhibit 99.1 for additional strategic details regarding the integration of Trent Drugs.